PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study
| Autor: | Philip Eclarinal, Karen A. Kurdziel, Cathy D. Vocke, Nana Yaqub-Ogun, Stephen Adler, W. Marston Linehan, Yolanda McKinney, Baris Turkbey, Adam R. Metwalli, Miriam R. Anver, Frank I. Lin, Juanita Weaver, Gennady Bratslavsky, Peter L. Choyke, Maria J. Merino, Maria Liza Lindenberg, Gideon Kwarteng |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Pathology Imaging biomarker Urology Contrast Media Pilot Projects Malignancy Multimodal Imaging Article 030218 nuclear medicine & medical imaging Diagnosis Differential 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Fluorodeoxyglucose F18 Internal medicine Parenchyma Biomarkers Tumor Medicine Humans Radiology Nuclear Medicine and imaging Cyst Prospective Studies Carcinoma Renal Cell Aged Carbonic Anhydrases Kidney Sulfonamides Radiological and Ultrasound Technology business.industry Gastroenterology Dipeptides Hepatology Middle Aged medicine.disease Kidney Neoplasms Clear cell renal cell carcinoma medicine.anatomical_structure 030220 oncology & carcinogenesis Positron-Emission Tomography Female Radiopharmaceuticals business Tomography X-Ray Computed |
| Zdroj: | Abdom Radiol (NY) |
| Popis: | BACKGROUND: Carbonic anhydrase IX (CA-IX) is a potential imaging biomarker of clear cell renal cell carcinoma (ccRCC). Here, we report the results of a phase II clinical trial of a small molecule radiotracer targeting CA-IX ((18)F-VM4-037) in ccRCC. 11 patients with kidney masses underwent (18)F-VM4-037 PET/CT prior to surgery. Dynamic imaging was per-formed for the first 45 min post injection and whole-body imaging was obtained at 60 min post injection. Tumors were surgically excised or biopsied within 4 weeks of imaging. RESULTS: All patients tolerated the radiotracer well with no adverse events. Ten of the 11 patients had histologically confirmed malignancy. One patient had a Bosniak Type 3 cyst with no tumor found at surgery. Two patients had extrarenal disease and 9 had tumors only in the kidney. Primary ccRCC lesions were difficult to visualize on PET alone due to high uptake of the tracer in the adjacent normal kidney parenchyma, however when viewed in conjunction with CT, the tumors were easily localized. Metastatic lesions were clearly visible on PET. Mean SUV for primary kidney lesions was 2.55 in all patients; in patients with histologically confirmed ccRCC, the mean SUV was 3.16. The time-activity curves (TAC) are consistent with reversible ligand binding with peak activity concentration at 8 min post injection followed by washout. Distribution Volume Ratio (DVR) of the lesions was measured using the Logan graphical analysis method. The mean DVR value across the 9 kidney lesions was 5.2 ± 2.8, (range 0.68–10.34). CONCLUSION: 18F-VM4-037 is a well-tolerated PET agent that allows same day imaging of CA-IX expression. The agent demonstrated moderate signal uptake in primary tumors and excellent visualization of CA-IX positive metastases. While the evaluation of primary ccRCC lesions is challenging due to high background activity in the normal kidney parenchyma, 18F-VM4-037 may be most useful in the evaluation of metastatic ccRCC lesions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|